175 related articles for article (PubMed ID: 34344667)
1. Disregarding the restrictive vial-opening policy for BCG vaccine in Guinea-Bissau: impact and cost-effectiveness for tuberculosis mortality and all-cause mortality in children aged 0-4 years.
Thysen SM; Fisker AB; Byberg S; Aaby P; Roy P; White R; Griffiths U; Harris RC
BMJ Glob Health; 2021 Aug; 6(8):. PubMed ID: 34344667
[TBL] [Abstract][Full Text] [Related]
2. Non-restrictive open vial policy combined with the home visit vaccinations for improving BCG coverage in a high-incidence outreach region: A model-based cost-effectiveness analysis for Indonesia.
Machlaurin A; Luttjeboer J; Setiawan D; Sytse van der Werf T; Postma MJ
J Glob Health; 2023 May; 13():04049. PubMed ID: 37227042
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau.
Byberg S; Fisker AB; Thysen SM; Rodrigues A; Enemark U; Aaby P; Benn CS; Griffiths UK
Glob Health Action; 2017; 10(1):1329968. PubMed ID: 28580855
[TBL] [Abstract][Full Text] [Related]
4. BCG coverage and barriers to BCG vaccination in Guinea-Bissau: an observational study.
Thysen SM; Byberg S; Pedersen M; Rodrigues A; Ravn H; Martins C; Benn CS; Aaby P; Fisker AB
BMC Public Health; 2014 Oct; 14():1037. PubMed ID: 25282475
[TBL] [Abstract][Full Text] [Related]
5. The real-life number of neonatal doses of Bacille Calmette-Guérin vaccine in a 20-dose vial.
Schaltz-Buchholzer F; Frankel HN; Benn CS
Glob Health Action; 2017; 10(1):1-4. PubMed ID: 28169606
[TBL] [Abstract][Full Text] [Related]
6. The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality.
Harris RC; Dodd PJ; White RG
BMC Med; 2016 Sep; 14(1):138. PubMed ID: 27633883
[TBL] [Abstract][Full Text] [Related]
7. Household costs of seeking BCG vaccination in rural Guinea-Bissau.
Thysen SM; Byberg S; Martins JSD; Kallestrup P; Griffiths UK; Fisker AB
Vaccine; 2019 Sep; 37(37):5505-5508. PubMed ID: 31405635
[TBL] [Abstract][Full Text] [Related]
8. Can BCG vaccination at first health-facility contact reduce early infant mortality? Study protocol for a cluster-randomised trial (CS-BCG).
Thysen SM; Møller Jensen A; Vedel JO; da Silva Borges I; Aaby P; Jensen AKG; Benn CS; Fisker AB
BMJ Open; 2022 Nov; 12(11):e063872. PubMed ID: 36410811
[TBL] [Abstract][Full Text] [Related]
9. Low birth weight infants and Calmette-Guérin bacillus vaccination at birth: community study from Guinea-Bissau.
Roth A; Jensen H; Garly ML; Djana Q; Martins CL; Sodemann M; Rodrigues A; Aaby P
Pediatr Infect Dis J; 2004 Jun; 23(6):544-50. PubMed ID: 15194836
[TBL] [Abstract][Full Text] [Related]
10. Neonatal BCG vaccination and child survival in TB-exposed and TB-unexposed children: a prospective cohort study.
Thysen SM; Benn CS; Gomes VF; Rudolf F; Wejse C; Roth A; Kallestrup P; Aaby P; Fisker A
BMJ Open; 2020 Feb; 10(2):e035595. PubMed ID: 32114478
[TBL] [Abstract][Full Text] [Related]
11. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.
Fu H; Lin HH; Hallett TB; Arinaminpathy N
Vaccine; 2018 Sep; 36(39):5902-5909. PubMed ID: 30143270
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.
Tseng CL; Oxlade O; Menzies D; Aspler A; Schwartzman K
BMC Public Health; 2011 Jan; 11():55. PubMed ID: 21269503
[TBL] [Abstract][Full Text] [Related]
13. Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: epidemiologic and economic assessment.
Altes HK; Dijkstra F; Lugnèr A; Cobelens F; Wallinga J
Epidemiology; 2009 Jul; 20(4):562-8. PubMed ID: 19295437
[TBL] [Abstract][Full Text] [Related]
14. BCG scarring and improved child survival: a combined analysis of studies of BCG scarring.
Benn CS; Roth A; Garly ML; Fisker AB; Schaltz-Buchholzer F; Timmermann A; Berendsen M; Aaby P
J Intern Med; 2020 Dec; 288(6):614-624. PubMed ID: 32301189
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial.
Pereira SM; Barreto ML; Pilger D; Cruz AA; Sant'Anna C; Hijjar MA; Ichihara MY; Santos AC; Genser B; Rodrigues LC
Lancet Infect Dis; 2012 Apr; 12(4):300-6. PubMed ID: 22071248
[TBL] [Abstract][Full Text] [Related]
16. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.
Dye C
J R Soc Interface; 2013 Oct; 10(87):20130365. PubMed ID: 23904584
[TBL] [Abstract][Full Text] [Related]
17. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?
Aaby P; Roth A; Ravn H; Napirna BM; Rodrigues A; Lisse IM; Stensballe L; Diness BR; Lausch KR; Lund N; Biering-Sørensen S; Whittle H; Benn CS
J Infect Dis; 2011 Jul; 204(2):245-52. PubMed ID: 21673035
[TBL] [Abstract][Full Text] [Related]
19. BCG vaccination scar associated with better childhood survival in Guinea-Bissau.
Roth A; Gustafson P; Nhaga A; Djana Q; Poulsen A; Garly ML; Jensen H; Sodemann M; Rodriques A; Aaby P
Int J Epidemiol; 2005 Jun; 34(3):540-7. PubMed ID: 15659474
[TBL] [Abstract][Full Text] [Related]
20. Development of BCG Scar and Subsequent Morbidity and Mortality in Rural Guinea-Bissau.
Storgaard L; Rodrigues A; Martins C; Nielsen BU; Ravn H; Benn CS; Aaby P; Fisker AB
Clin Infect Dis; 2015 Sep; 61(6):950-9. PubMed ID: 26060293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
